ESMO 2023

Givastomig: brief review of its R&D progress and the clinical result in 2023 ESMO

16 November 2023
4 min read

The recent ESMO Congress presented noteworthy clinical trial results of Givastomig, paving the way for a detailed exploration of its therapeutic potential in solid tumors.

Givastomig's R&D Progress

Givastomig is a bispecific antibody drug that targets two proteins, 4-1BB and CLDN18.2, in the field of biomedicine. It is being developed by I-MAB Biopharma Co., Ltd. The drug has shown potential therapeutic applications in various areas, including neoplasms, digestive system disorders, and endocrinology and metabolic diseases. 

According to the Patsnap Synapse, Givastomig is currently in Phase 1 of clinical trials globally . And the clinical trial areas for Givastomig are primarily in the China and United States. The key indication is Metastatic Solid Tumor.

Detailed Clinical Result of Givastomig

The sequential assignment, open-labeled clinical trial (NCT04900818) was aimed to evaluate the safety, clinical response (RECIST v1.1), pharmacokinetics (PK), soluble 4-1BB (s4-1BB) levels, serum cytokines and immunophenotypes of Givastomig. 

In this study, Givastomig was administered intravenously every 2 weeks (Q2W) across 8 dose levels (0.1-15mg/kg) in patients with advanced solid tumors. The Bayesian Optimal Interval design was utilized during dose escalation without CLDN18.2 preselection. Additionally, 6 CLDN18.2+ patients per dose level were enrolled at 5, 8, and 12mg/kg in parallel expansions. CLDN18.2+ is defined as ≥1% of tumor cells with ≥1+ intensity by immunohistochemistry. 

The result showed that As of 18 April 2023, 50 patients were enrolled (32 in the dose escalation and 18 in the parallel expansions) with a median age of 66 years, ECOG 0/1 (34%/66%), and a median of 3 prior lines of therapy. No dose-limiting toxicity was observed up to 15 mg/kg, and maximum tolerated dose was not reached. The most common treatment-related adverse events (TRAEs) were Grade 1/2 nausea (22%), fatigue (14%), and vomiting (12%) with 7 sporadic Grade 3 TRAEs, and no Grade ≥4 TRAEs. Givastomig exhibited a linear PK at doses ≥5 mg/kg and a dose-dependent increase of s4-1BB levels reaching a plateau at doses ≥8 mg/kg. Among 18 efficacy-evaluable patients with CLDN18.2+ gastroesophageal cancer (GEC) at 5, 8, and 12mg/kg, partial response (PR) in 1 patient each at 5 and 8 mg/kg, unconfirmed PR in 2 patients at 12 mg/kg, and stable disease in 2 patients were observed. An additional PR was observed in 1 patient with head and neck cancer at 12mg/kg. CLDN18.2 expression among the responders ranged from 11% to 100%.

It can be concluded that Givastomig is well tolerated up to 15 mg/kg Q2W. Encouraging monotherapy activity was observed in heavily pre-treated GEC patients with a wide range of CLDN18.2 expression, including low CLND18.2 tumors. The PK profile, s4-1BB induction, and efficacy signal support 12 mg/kg as an optimal dose. Further development of givastomig mono- and combo- therapy in GEC and other cancers is planned.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

Enzyme Gene Mutations Sequences and Patent Acquisition Strategies
Bio Sequence
2 min read
Enzyme Gene Mutations Sequences and Patent Acquisition Strategies
16 November 2023
A ketoreductase enzyme has undergone a gene mutation at a certain mutation site and has acquired a mutant enzyme with higher activity. How can one search for publicly available sequences of such enzyme mutants, as well as other popular mutation sites?
Read →
What are CDK2 inhibitors and how do you quickly get the latest development progress?
What are CDK2 inhibitors and how do you quickly get the latest development progress?
16 November 2023
Small-molecule CDK2 selective inhibitors would be significant chemical probes for dissecting cellular processes or understanding the basics of diseases.
Read →
GB-1211: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
4 min read
GB-1211: brief review of its R&D progress and the clinical result in 2023 ESMO
16 November 2023
On 23 Oct 2023, GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) was reported at the ESMO Congress.
Read →
Efficient Strategies for Acquiring Sequence Information for an Antibody by Its Name
Bio Sequence
2 min read
Efficient Strategies for Acquiring Sequence Information for an Antibody by Its Name
16 November 2023
This article will teach you three methods to find the corresponding sequence information by the name of an antibody.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.